The partial agonist inside the leaf
IUPAC: methyl (E)-2-[(2S,3S,12bS)-3-ethyl-8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate · C23H30N2O4 · MW 398.50 g/mol · CAS 4098-40-2
Mitragynine. The principal alkaloid of kratom (Mitragyna speciosa), a Southeast-Asian coffee-family tree whose leaves have been chewed and brewed for centuries. Mitragynine is a low-efficacy, G-protein-biased µ-opioid partial agonist — but the pharmacology that matters most is downstream: the body converts it into 7-hydroxymitragynine (more efficacious) and, in the lab, the rearranged mitragynine pseudoindoxyl (sub-nanomolar). Names: kratom, ketum, kakuam, biak, thang.
Mitragynine engages the µ-opioid receptor (MOR) — the same Gi/o-coupled receptor as morphine and fentanyl — but it is not a full agonist. In binding it is respectable (Ki ≈ 7.2 nM at human MOR, Váradi 2016), yet its intrinsic efficacy is low: in [35S]GTPγS and cAMP assays mitragynine drives only a fraction of the G-protein response of DAMGO or morphine. Affinity is not efficacy. That ceiling is the single most important fact about the molecule.
Crucially, mitragynine and its analogs fail to recruit β-arrestin-2 even at 10 µM (Váradi 2016; Kruegel 2016) — they are G-protein biased. Classical opioids (morphine, DAMGO, fentanyl) recruit β-arrestin-2 robustly; mitragynine engages the receptor's transducer machinery on the Gi side almost exclusively. At δ (DOR) and κ (KOR) receptors mitragynine behaves as a competitive antagonist, not an agonist — a mixed opioid profile that shapes both its analgesia and its distinctive withdrawal.
Mitragynine occupies the MOR orthosteric pocket (Ki ~7.2 nM) and stabilizes an active-state conformation that couples Gi, inhibiting adenylyl cyclase and cAMP. Its low intrinsic efficacy imposes a ceiling on maximal MOR signaling — the pharmacological basis of a wider therapeutic window than full agonists.
No detectable β-arrestin-2 recruitment up to 10 µM. Because GRK/β-arrestin engagement drives receptor internalization and (per the classical hypothesis) some on-target opioid toxicity, biased signaling was proposed to spare respiration and gut — though the bias-vs-efficacy debate is unsettled (see §03).
Oxidation at C7 (CYP3A4) yields 7-OH-mitragynine — a more efficacious MOR partial agonist (Ki ~13.5 nM) and the true mediator of kratom's analgesia in vivo (Kruegel 2019). Present at only ~2% of mitragynine in leaf, but potent, and the site of most abuse liability.
A spiro-pseudoindoxyl rearrangement of the indole reshapes the scaffold into a sub-nanomolar MOR agonist (Ki ~0.09 nM) that is also a DOR antagonist (Ki ~3 nM) and still β-arrestin-2–silent (Váradi 2016). This is the ligand captured in PDB 7T2G. ~80× mitragynine's affinity.
Mitragynine has functional activity at α2-adrenoceptors (clonidine-like), contributing to its use for opioid-withdrawal symptom relief and part of the sedative/hypotensive tail at higher doses. A genuinely non-opioid arm of the pharmacology (Obeng 2020; 2024–2025 α-adrenoceptor studies).
Reported interactions at 5-HT2A/5-HT2C (antagonist-leaning), adenosine, D2, and postsynaptic receptors help explain the biphasic "stimulant-low / opioid-high" subjective profile. These are secondary and less quantitatively pinned than the opioid arm.
Kratom is taken orally — chewed leaf, brewed "tea," or crushed-leaf capsules — so mitragynine's pharmacology is filtered through first-pass metabolism. Oral bioavailability is low and variable (single-digit percent in animal models), but the parent alkaloid is long-lived: human PK in chronic users found a terminal half-life near 23 hours with an early Tmax under ~1 hour (Trakulsrichai 2015). It is highly lipophilic, extensively protein-bound, and has a large volume of distribution.
Metabolic activation, not inactivation. The headline PK story is that CYP3A4 oxidizes mitragynine at C7 to 7-hydroxymitragynine — a metabolite more capable of producing MOR-mediated analgesia than the parent. Mitragynine is thus partly a prodrug for its own active metabolite. Because mitragynine also inhibits CYP2D6, CYP3A4, CYP2C9 and P-glycoprotein, it is a real perpetrator of drug–drug interactions (see §06).
The harm-reduction-relevant claim is real but must be stated carefully. Classical full µ-agonists (fentanyl, morphine, heroin) drive MOR signaling to its maximum, and at sufficient dose they suppress the brainstem pre-Bötzinger respiratory rhythm until breathing stops. Mitragynine's low intrinsic efficacy caps how hard it can push that circuit; 7-hydroxymitragynine is more efficacious but still partial. In animal respiratory-depression models and in human epidemiology, kratom alone shows a markedly lower respiratory-arrest signal than classical opioids, and near-total naloxone reversibility confirms the effect is MOR-driven.
Two mechanisms were proposed for the wider window: (1) G-protein bias — no β-arrestin-2 recruitment — following the βarr2-knockout literature that linked arrestin to respiratory depression and constipation; and (2) simple low efficacy. The honest position in 2026 is that the bias hypothesis has been substantially challenged: βarr2-knockout mice still depress respiration, and re-analysis (Gillis 2020; Kliewer 2020) argues that low intrinsic efficacy — not bias per se — explains most of the therapeutic-window advantage of biased/partial ligands. Either way, the safety comes from a ceiling on efficacy, and that ceiling is defeated by dose stacking and depressant combinations.
Kratom's folk reputation — energizing at low doses, sedating and analgesic at high doses — is not marketing; it falls out of a multi-target profile. Low doses foreground the adrenergic/serotonergic and postsynaptic effects; higher doses recruit progressively more MOR signaling (and more 7-OH exposure), tipping the experience toward classical opioid territory: analgesia, anxiolysis, warmth, itch, pupillary constriction, and dose-dependent sedation.
MOR Gi coupling in the periaqueductal gray, rostral ventromedial medulla, and dorsal horn produces antinociception; MOR in the VTA→NAcc pathway disinhibits dopamine and generates reward. Because efficacy is capped and 7-OH exposure is limited from leaf, the euphoria and reinforcement are typically milder than full-agonist opioids — but they are real, dose-dependent, and larger for 7-OH-enriched products.
Functional α2-adrenoceptor activity in the locus coeruleus and periphery dampens sympathetic outflow — sedation, mild hypotension, and suppression of the noradrenergic storm that drives opioid withdrawal. This is why kratom can blunt withdrawal from classical opioids, and it is a mechanistically distinct, non-MOR contribution (Obeng 2020; α-adrenoceptor pharmacology 2024–2025).
Reported activity at 5-HT2A/5-HT2C (antagonist-leaning), adenosine A2A, dopamine D2, and other sites contributes to the low-dose "coffee-plus" stimulation, mood lift, and appetite effects. These targets are less quantitatively characterized than the opioid arm and vary across preparations and chemovars.
Daily heavy use produces genuine physical dependence via MOR adaptation: upregulated cAMP/adenylyl-cyclase superactivation and downstream tolerance. Withdrawal is real but generally milder and shorter than classical-opioid withdrawal for leaf-based use — irritability, myalgia, rhinorrhea, insomnia, GI upset, craving. 7-OH-enriched/semi-synthetic concentrates markedly raise dependence and abuse liability toward classical-opioid levels.
Most fatalities in which kratom is detected are polydrug deaths — other opioids, benzodiazepines, alcohol, gabapentinoids — not kratom alone. But two adulteration patterns turn a comparatively forgiving partial agonist into a lethal product.
"Krypton": a notorious commercial kratom product spiked with O-desmethyltramadol — the active µ-agonist metabolite of tramadol. Adding a full-blooded synthetic opioid (plus tramadol's serotonergic and seizure-lowering baggage) to kratom erases the efficacy ceiling that makes leaf relatively safe. A cluster of fatal "krypton" poisonings in Sweden (Kronstrand et al., 2011) is the textbook case: users believed they were taking herbal kratom.
Semi-synthetic 7-OH products: the newer and larger danger. Concentrated 7-hydroxymitragynine tablets/"shots" marketed since ~2023–2025 deliver the potent, efficacious metabolite directly and at doses far above anything achievable from leaf. These are pharmacologically much closer to classical opioids — higher euphoria, higher dependence, higher overdose potential — and are the focus of 2024–2026 regulatory alarm. "Kratom" on a label no longer tells you what is in the bottle.
Contaminants & inconsistency: unregulated products have carried heavy metals, Salmonella, and wildly variable alkaloid content between and within brands. Dose from one batch does not predict the next.
The mitragynine scaffold is a pentacyclic indolo[2,3-a]quinolizidine — a fused, conformationally restrained "corynanthe"
cage carrying two flexible appendages: the C3 ethyl group and the β-methoxyacrylate/enol-ether side chain. In FlexAID∆S terms the rigid core
keeps the ΔS_conf penalty on binding modest — the molecule arrives largely pre-organized — while the side chain is the
entropic price paid to lock the pharmacophore contacts. Mitragynine's affinity (Ki ~7 nM) is decent; its problem is
efficacy, i.e. how much conformational work it does on the receptor once bound.
The pseudoindoxyl rearrangement is an entropy story with teeth. Converting the flat indole into a spiro-pseudoindoxyl adds
a carbonyl and repuckers the top face so the ligand plunges deeper into the MOR pocket (visualized in PDB 7T2G), buying
new H-bond and van-der-Waals contacts. Affinity jumps ~80-fold to sub-nanomolar (Ki ~0.09 nM). In Shannon terms the unbound-pocket
entropy H_pocket collapses hard onto a single high-complementarity conformer — the classic entropy-collapse fingerprint
of a high-affinity agonist, sharper here than for the loosely-held parent.
The G-protein bias is best read on the transducer side of the entropy ledger: a ligand that couples Gi but never licenses the GRK-phosphorylated, β-arrestin-competent state is stabilizing a narrower receptor conformational ensemble — a lower-entropy basin on the intracellular face that simply does not sample the arrestin-binding geometry. Whether that narrowing (bias) or the shallow overall activation (low efficacy) is what spares breathing is exactly the unresolved question of §03.
Order-of-magnitude thermodynamics from the measured constants: ΔG = −RT·ln(1/Ki) at 298 K gives
≈ −11.1 kcal/mol for mitragynine (7.2 nM) and ≈ −13.8 kcal/mol for mitragynine pseudoindoxyl (0.09 nM) —
a ~2.7 kcal/mol gain bought almost entirely by the pseudoindoxyl's added enthalpic contacts at low conformational-entropy cost.
Kratom is genuinely lower-risk than classical opioids taken alone as leaf — and that is exactly why the dangerous scenarios are combinations, concentrates, and adulterants. Naloxone works. Dependence is real. None of this is moral; it is dose-response.
EIG), Zhao / Uprety / Che / Majumdar et al. This is a real kratom-alkaloid co-structure — the pseudoindoxyl metabolite, not the parent mitragynine.
Rotate · scroll to zoom · right-drag to translate.
| Target | Affinity | Rel. | Action |
|---|---|---|---|
|
MOR · mitragynine
µ-opioid receptor (OPRM1)
|
Ki ≈ 7.2 nM
low intrinsic efficacy
|
Partial agonist | |
|
MOR · 7-OH-MG
7-hydroxymitragynine (metabolite)
|
Ki ≈ 13.5 nM
more efficacious
|
Partial agonist | |
|
MOR · pseudoindoxyl
Mitragynine pseudoindoxyl (7T2G)
|
Ki ≈ 0.09 nM
sub-nanomolar
|
Full agonist | |
|
DOR · pseudoindoxyl
δ-opioid receptor (OPRD1)
|
Ki ≈ 3 nM
δ block on MP
|
Antagonist | |
|
DOR / KOR · mitragynine
δ- & κ-opioid receptors
|
weaker than MOR
competitive block
|
Antagonist | |
|
α2-AR · mitragynine
α2-adrenoceptor
|
functional activity
no firm human Ki
|
Clonidine-like |